SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-035693
Filing Date
2022-06-29
Accepted
2022-06-29 08:00:23
Documents
13
Period of Report
2022-06-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea161465-8k_actinium.htm   iXBRL 8-K 27223
2 AMENDED AND RESTATED CAPITAL ON DEMANDTM SALES AGREEMENT BY AND BETWEEN ACTINIUM ea161465ex1-1_actinium.htm EX-1.1 291295
  Complete submission text file 0001213900-22-035693.txt   556165

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnm-20220628.xsd EX-101.SCH 3051
4 XBRL LABEL FILE atnm-20220628_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE atnm-20220628_pre.xml EX-101.PRE 22607
7 EXTRACTED XBRL INSTANCE DOCUMENT ea161465-8k_actinium_htm.xml XML 3610
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 221051811
SIC: 2834 Pharmaceutical Preparations